Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay

作者: Paul R. Burchard , Saurabh Malhotra , Prabhjot Kaur , Gregory J. Tsongalis

DOI: 10.1016/J.CANCERGEN.2013.03.002

关键词: Wild typeReceptorGenotypeMolecular biologyMelting curve analysisBiologyCD16FCGR3APolymerase chain reactionTaqManGeneticsCancer research

摘要: The fragment crystallizable (Fc) region of the immunoglobulin G, low affinity III A receptor (FCGR3a, also known as CD16) belongs to Fc gamma family (FCGR), which plays an important role in immunoinflammatory processes. It is a affinity, transmembrane that mainly expressed monocytes, natural killer cells, and macrophages. has been implicated various inflammatory conditions, recently polymorphism (rs396991) this gene shown influence response rituximab (anti-CD20) therapy disorders. We evaluated two molecular methods genotype polymorphism. Archived, formalin-fixed, paraffin-embedded samples from 26 biopsies diffuse large B-cell lymphoma were retrieved DNA was extracted. tested for FCGR3a using real-time polymerase chain reaction (PCR) followed by melt curve analysis or standard TaqMan allelic discrimination assay ABI 7500 FAST PCR instrument. With assay, we found 16 cases wild type genotype, homozygous phenylalanine (F/F), receptor, whereas had valine (V/V) eight heterozygous with V/F genotype. Results similar 25 cases; however, four did not have sufficient method, result one sample discordant. new offers several advantages over previously published assays, such faster turnaround time ease interpretation. These performance characteristics make it highly suitable use clinical laboratory.

参考文章(32)
Walter A Wuillemin, Johanna A Kremer Hovinga, Axel Rüfer, Bernhard Lämmle, Doreen Brodmann, Michael Gregor, Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Medical Weekly. ,vol. 137, pp. 518- 524 ,(2007) , 10.4414/SMW.2007.11908
Toshiyuki Takai, Roles of Fc receptors in autoimmunity Nature Reviews Immunology. ,vol. 2, pp. 580- 592 ,(2002) , 10.1038/NRI856
JY Chen, CM Wang, JM Wu, HH Ho, Shue-Feng Luo, None, Association of rheumatoid factor production with FcγRIIIa polymorphism in Taiwanese rheumatoid arthritis Clinical and Experimental Immunology. ,vol. 144, pp. 10- 16 ,(2006) , 10.1111/J.1365-2249.2006.03021.X
G�ls�m Emel Pamuk, Salim Donmez, Burhan Turgut, Muzaffer Demir, Ozden Vural, Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. American Journal of Hematology. ,vol. 78, pp. 81- 81 ,(2005) , 10.1002/AJH.20218
Anis Toumeh, Navpreet Josh, Rawan Narwal, Ragheb Assaly, Refractory thrombotic thrombocytopenic purpura associated with primary Sjogren syndrome treated with rituximab: a case report. American Journal of Therapeutics. ,vol. 21, ,(2014) , 10.1097/MJT.0B013E3182459AA0
Antonio Nieto, Rafael Cáliz, María Pascual, Luis Matarán, Sergio García, Javier Martín, Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis Arthritis & Rheumatism. ,vol. 43, pp. 735- 739 ,(2000) , 10.1002/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q
D Papaioannou, R Rafia, J Rathbone, M Stevenson, H Buckley Woods, J Stevens, Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technology Assessment. ,vol. 16, pp. 1- ,(2012) , 10.3310/HTA16370